UniSuper Management Pty Ltd Purchases 1,400 Shares of Edwards Lifesciences Corporation $EW

UniSuper Management Pty Ltd boosted its stake in Edwards Lifesciences Corporation (NYSE:EW) by 2.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 52,045 shares of the medical research company’s stock after purchasing an additional 1,400 shares during the quarter. UniSuper Management Pty Ltd’s holdings in Edwards Lifesciences were worth $3,772,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in the stock. Parkman Healthcare Partners LLC boosted its stake in Edwards Lifesciences by 38.3% in the 1st quarter. Parkman Healthcare Partners LLC now owns 200,819 shares of the medical research company’s stock worth $14,555,000 after purchasing an additional 55,605 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Edwards Lifesciences by 1.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 100,887 shares of the medical research company’s stock worth $7,311,000 after purchasing an additional 1,442 shares during the period. Hawk Ridge Capital Management LP bought a new position in Edwards Lifesciences in the 1st quarter worth about $19,132,000. Edmond DE Rothschild Holding S.A. boosted its stake in Edwards Lifesciences by 2.5% in the 1st quarter. Edmond DE Rothschild Holding S.A. now owns 661,448 shares of the medical research company’s stock worth $47,942,000 after purchasing an additional 15,861 shares during the period. Finally, AQR Capital Management LLC boosted its stake in Edwards Lifesciences by 339.7% in the 1st quarter. AQR Capital Management LLC now owns 918,537 shares of the medical research company’s stock worth $65,381,000 after purchasing an additional 709,648 shares during the period. Institutional investors own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

EW has been the subject of several analyst reports. Stifel Nicolaus raised their target price on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Friday, July 25th. JPMorgan Chase & Co. raised their target price on Edwards Lifesciences from $80.00 to $85.00 and gave the stock a “neutral” rating in a research note on Friday, July 25th. Morgan Stanley raised their price target on Edwards Lifesciences from $75.00 to $81.00 and gave the company an “equal weight” rating in a report on Tuesday, July 15th. BTIG Research raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 price target on the stock in a report on Tuesday, July 29th. Finally, Wells Fargo & Company raised their price target on Edwards Lifesciences from $84.00 to $88.00 and gave the company an “overweight” rating in a report on Thursday, August 7th. Three research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $85.90.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $80.28 on Tuesday. The stock has a market cap of $47.13 billion, a P/E ratio of 11.55, a PEG ratio of 3.90 and a beta of 1.07. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a twelve month low of $64.00 and a twelve month high of $83.00. The business’s 50-day moving average price is $78.80 and its two-hundred day moving average price is $75.26.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.05. The company had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.Edwards Lifesciences’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period last year, the firm posted $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, equities analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 4,114 shares of the firm’s stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the transaction, the vice president directly owned 22,002 shares of the company’s stock, valued at approximately $1,748,278.92. This trade represents a 15.75% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Larry L. Wood sold 8,950 shares of the firm’s stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $75.23, for a total value of $673,308.50. Following the transaction, the insider directly owned 206,900 shares in the company, valued at approximately $15,565,087. This represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 22,014 shares of company stock worth $1,698,844. 0.34% of the stock is currently owned by insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.